All In Biotech

Drug Trial Radar · NCT03420014

Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)

A Randomized Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Metastatic Leiomyosarcoma

Last checked: Nov 19, 2026Latest source record: Oct 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 114 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

114

Planned (sponsor's estimate)

Start

Dec 27, 2018

Primary completion

Dec 2024

Study completion Dec 2025

Sponsor

Lead sponsor
Philogen S.p.A.Industry
Sponsor type
Industry
First posted
Feb 5, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The present study is an open-label, randomized, controlled, two-arm multi-center study of the efficacy of L19TNF treatment in combination with doxorubicin versus doxorubicin alone in metastatic leiomyosarcoma patients.

Conditions

  • Leiomyosarcoma

Interventions

  • DoxorubicinDrug

    75 mg/m2 doxorubicin will be administered once every 3 weeks (Day 1 of every 21-days cycle).

  • L19TNF plus doxorubicinCombination product

    13 μg/kg L19TNF will be administered on day 1, 3 and 5 of every 21-days cycle in combination with 60 mg/m2 doxorubicin on day 1 of every 21-days cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS)Time frame: From randomization up to week 72

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital

    Phoenix, Arizona · Recruiting

  • Sarcoma Oncology Research Center (SORC) Cancer Center of Southern California

    Santa Monica, California · Recruiting

  • Mayo Clinic Hospital

    Jacksonville, Florida · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • Rutgers Cancer Institute of New Jersey 195 Little Albany Street New Brunswick, NJ 08901 Room 2031

    New Brunswick, New Jersey · Recruiting

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • Seattle Cancer Care Alliance 825 Eastlake Ave. E. Seattle, WA 98109 Mail Stop CE2-128

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.